Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 372-380

  Bhavnani, Sujata M ^a   Hammel, Jeffrey P ^a   Van Wart, Scott A ^a   Rubino, Christopher M ^a   Reynolds, Daniel K ^a,e   Forrest, Alan ^a   Drusano, George L ^b   Khariton, Tatiana ^c   Friedland, H David ^d   Riccobene, Todd A ^c   Ambrose, Paul G ^a  

^a INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c FOREST RESEARCH INSTITUTE   (United States)

^d Cerexa Inc   (United States)

^e Capital District Physicians' Health Plan   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CEFTAROLINE FOSAMIL; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PPI-0903;

AGE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL SKIN DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKIN INFECTION; SKIN STRUCTURE; STEADY STATE; CLINICAL TRIAL; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; SKIN; STAPHYLOCOCCAL SKIN INFECTIONS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SKIN; STAPHYLOCOCCAL SKIN INFECTIONS; TREATMENT OUTCOME;

EID: 84920133705     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02531-14     Document Type: Article

References (30)

1. Bonapace CR. 2004. In vitro/animal models to support dosage selection: FDA perspective. IDSA/ISAP/FDA Workshop. 16 April 2004. U.S. Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads /Drugs/DrugSafety/InformationbyDrugClass/UCM187288.ppt.
2. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 44:79-86. http://dx.doi.org/10.1086/510079.
3. Forest Pharmaceuticals, Inc. 2013. Teflaro package insert. Forest Pharmaceuticals, Inc. St. Louis, MO.
4. AstraZeneca AB. 2012. Zinforo summary of product characteristics. AstraZeneca AB, Sodertalje, Sweden.
5. Talbot GH, Thye D, Das A, Ge Y. 2007. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 51:3612-3616. http://dx .doi.org/10.1128/AAC.00590-07.
6. Cerexa, Inc. 2012. Efficacy and safety of ceftaroline versus linezolid in subjects with complicated skin and skin structure infections. Clinical Trials.gov, Bethesda, MD. http://clinicaltrials.gov/show/NCT00633152.
7. Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T. 2010. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 65(Suppl 4):iv41-iv51. http://dx.doi.org/10.1093/jac/dkq254.
8. Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland HD, Baculik T. 2010. CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 65(Suppl 4):iv53-iv65. http://dx.doi.org/10.1093/jac/dkq255.
9. Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, Critchley I, Das AF, Thye D. 2010. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 51:641-650. http://dx.doi.org/10.1086/655827.
10. Andes D, Craig WA. 2006. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 50:1376-1383. http://dx.doi.org/10.1128/AAC.50.4.1376-1383.2006.
11. Van Wart SA, Forrest A, Khariton T, Rubino CM, Bhavnani SM, Riccobene TA, Ambrose PG. 2013. Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired pneumonia. J Clin Pharmacol 53:1155-1167. http://dx.doi.org/10.1002/jcph.153.
12. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. http://dx.doi.org/10.1159/000180580.
13. DuBois D, DuBois DF. 1916. A formula to estimate the approximate surface area if height and weight be known. Arch Int Med 17:863-871.
14. Sheiner LB, Beal SL. 1981. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512. http://dx.doi.org/10 .1007/BF01060893.
15. Systat Software, Inc. 2004. Systat 11, statistics II, Systat Software, Inc., Richmond, CA.
16. R Development Core Team. 2010. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.r-project.org.
17. Wilson SE, Solomkin JS, Le V, Cammarata SK, Bruss JB. 2003. A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid.AmJ Surg 185:369-375. http://dx.doi.org/10 .1016/S0002-9610(02)01411-3.
18. Hosmer DW, Lemeshow S. 1989. Applied logistic regression. Wiley, New York, NY.
19. Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN. 2013. Antimicrobial Susceptibility Testing Subcommittee of the ClinicalandLaboratory Standards Institute. Background and rationale for revised Clinical and Laboratory Standards Institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and aztreonam. Clin Infect Dis 56:1301-1309. http://dx.doi.org/10.1093/cid/cit017.
20. Bhavnani SM, Hammel JP, Jones RN, Sader HS, Ambrose PG. 2011. Pharmacokinetic-pharmacodynamic evaluations in support of in vitro interpretive criteria for fluoroquinolones against salmonellae and Enterobacteriaceae, abstr A2-043. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 17-20 September 2011.
21. Ambrose PG, Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Bhavnani SM, Ellis-Grosse E. 2009. Application of patient population-derived phar-macokinetic-pharmacodynamic relationships to tigecycline breakpoint determinationforstaphylococciandstreptococci. DiagnMicrobiolInfectDis 63:155-159. http://dx.doi.org/10.1016/j.diagmicrobio.2008.10.011.
22. Bhavnani SM, Dudley MN, Landersdorfer C, Drusano GL, Craig WA, Jones RN, Ambrose PG. 2010. Pharmacokinetic-pharmacodynamic basis for CLSI carbapenems susceptibility breakpoint changes, abstr A1-1382. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Boston, MA, 12-15 September, 2010.
23. Bhavnani SM, Iyer V, Hammel J, Forrest A, Rubino CM, Van Wart SA, Prakhya A, McCollam J, Ambrose PG. 2008. Pharmacokineticpharmacodynamic oritavancin efficacy in patients with complicated skin and skin-structure infection, abstr A-3563. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America, Washington DC, 25-28 October 2008.
24. Lipsky BA, Itani KMF, Weigelt JA, Joseph W, Paap CM, Reisman A, Myers DE, Huang DB. 2011. The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: results from three randomized controlled trials. Int J Infect Dis 15:e140-e146. http://dx.doi.org/10.1016/j.ijid.2010.10.003.
25. Geerlings SE, Hoepelman AIM. 1999. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 26:259-265. http://dx.doi.org/10.1111/j.1574-695X.1999.tb01397.x.
26. U.S. Food and Drug Administration. 2010. Guidance for industry (draft). Acute bacterial skin and skin structure infections: developing drugs for treatment. U.S. Food and Drug Administration, Rockville, MD.
27. U.S. Food and Drug Administration. 2013. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. U.S. Food and Drug Administration, Rockville, MD.
28. U.S. Food and Drug Administration. 2010. Briefing document for Anti-Infective Drugs Advisory Committee Meeting. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia and complicated skin and skin structure infections. U.S. Food and Drug Administration, Rockville, MD.
29. Friedland HD, O'Neal T, Biek D, Eckburg PB, Rank DR, Llorens L, Smith A, Witherell GW, Laudano JB, Thye D. 2012. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 56: 2231-2236. http://dx.doi.org/10.1128/AAC.05738-11.
30. Bhavnani SM, Hammel JP, Van Wart SA, Rubino CM, Davenport JM, McIntyre G, Ambrose PG. 2012. Pharmacokinetic-pharmacodynamic analysis for efficacy of JNJ-Q2 using phase 2 data from patients with acute bacterial skin and skin structure infections, abstr A-1962. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, 9-12 September, 2012.